APA (7th ed.) Citation

Y, G., AC, L., & JJ, G. (2025). The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022. Pharmaceutical medicine, 39(6), 445. https://doi.org/10.1007/s40290-025-00587-6

Chicago Style (17th ed.) Citation

Y, Ghawaa, Lin AC, and Guo JJ. "The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022." Pharmaceutical Medicine 39, no. 6 (2025): 445. https://doi.org/10.1007/s40290-025-00587-6.

MLA (9th ed.) Citation

Y, Ghawaa, et al. "The Utilization, Reimbursement, and Cost of Targeted Therapies for Duchenne Muscular Dystrophy (DMD) in US Medicaid Programs: A Descriptive Trend Analysis from 2017 to 2022." Pharmaceutical Medicine, vol. 39, no. 6, 2025, p. 445, https://doi.org/10.1007/s40290-025-00587-6.